The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Identification of ALK gene alterations in urothelial carcinoma (UC).
J. Bellmunt
Consultant or Advisory Role - Pfizer
S. Selvarajah
No relevant relationships to disclose
S. Rodig
No relevant relationships to disclose
M. Salido
No relevant relationships to disclose
I. Costa
No relevant relationships to disclose
B. Bellosillo
No relevant relationships to disclose
L. Werner
No relevant relationships to disclose
C. Namgyal
No relevant relationships to disclose
F. A. B. Schutz
No relevant relationships to disclose
F. Pons
No relevant relationships to disclose
R. O'Brien
No relevant relationships to disclose
J. Barretina
No relevant relationships to disclose
S. Signoretti
No relevant relationships to disclose
M. Loda
No relevant relationships to disclose
J. Albanell
No relevant relationships to disclose
T. K. Choueiri
No relevant relationships to disclose
D. M. Berman
No relevant relationships to disclose
P. W. Kantoff
No relevant relationships to disclose
J. E. Rosenberg
Consultant or Advisory Role - Pfizer (U)